InnoCare
China - Beijing
BiotechnologyFocus: Cancer Treatments
InnoCare is a life sciences company focused on Cancer Treatments.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Orelabrutinib
Neuromyelitis Optica Spectrum DisorderClinical Trials (1)
NCT05284175A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
N/A[14C]ICP-022
Healthy VolunteersClinical Trials (1)
NCT04441450ADME Study of [14C]ICP-022 in Healthy Males
N/AOrelabrutinib and placebo
Healthy SubjectClinical Trials (1)
NCT05660720Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
Phase 1ICP-488
PsoriasisClinical Trials (1)
NCT05451199A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
Phase 1ICP-022
Systemic Lupus ErythematosusClinical Trials (1)
NCT03189017A Phase I Study of ICP-022 in Healthy Subjects
Phase 1ICP-105
Solid TumorClinical Trials (1)
NCT03642834Study of ICP-105 in Solid Tumors Patients
Phase 1ICP-723
Advanced Solid TumorsClinical Trials (1)
NCT05537987Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05370755A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Phase 1ICP-332 Tablets
Healthy SubjectsClinical Trials (1)
NCT06530966Phase I Study of ICP-332 in Healthy Subjects
Phase 1ICP-248
Mature B-cell MalignanciesClinical Trials (1)
NCT06351527Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Phase 1ICP-033 tablet
Patients With Advanced Solid TumorsClinical Trials (1)
NCT05367232A Study of ICP-033 in Patients With Advanced Solid Tumors
Phase 1Orelabrutinib + Rifampin
Healthy PersonClinical Trials (1)
NCT05316857DDI Study of Orelabrutinib
Phase 1ICP-332
Healthy SubjectsClinical Trials (1)
NCT05399030A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects
Phase 1ICP-248
Acute Myelogenous LeukemiaClinical Trials (1)
NCT06656494ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Phase 1ICP-248
Hematological MalignanciesClinical Trials (1)
NCT05728658The Study of ICP-248 in Patients With Mature B-cell Malignancies
Phase 1Clinical Trials (1)
NCT05690581Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Phase 1Orelabrutinib Tablets
Hepatic ImpairmentClinical Trials (1)
NCT05684653Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
Phase 1ICP-B794
Advanced Solid TumorsClinical Trials (1)
NCT07136558Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
Phase 1ICP-022
Systemic Lupus ErythematosusClinical Trials (1)
NCT04305197A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
Phase 1/2ICP-723
Solid TumorsClinical Trials (1)
NCT04685226A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Phase 1/2Orelabrutinib
Part 1：r/r B-cell MalignanciesClinical Trials (1)
NCT04014205A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT06845241Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2Drug ICP-192
Advanced Solid TumorsClinical Trials (1)
NCT04565275A Study of ICP-192 in Patients With Advanced Solid Tumors
Phase 1/2ICP-022
Mantle Cell LymphomaClinical Trials (1)
NCT03494179A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT05745623Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Phase 1/2CM355
HematomaClinical Trials (1)
NCT05210868A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1/2Orelabrutinib
B-cell Lymphoma RecurrentClinical Trials (1)
NCT04304040A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Phase 1/2ICP-022
CLL/SLLClinical Trials (1)
NCT03493217A Study to Evaluate ICP-022 in Patients With CLL/ SLL
Phase 1/2ICP-192
Solid TumorClinical Trials (1)
NCT03758664Clinical Study of ICP-192 in Solid Tumors Patients
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT05719701Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2ICP-192
Advanced Solid TumorClinical Trials (1)
NCT05372120A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
Phase 2Phase 2
Clinical Trials (1)
NCT04440059A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
Phase 2ICP-488 Tablets
Moderate to Severe Plaque PsoriasisClinical Trials (1)
NCT06109818Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
Phase 2Phase 2
Clinical Trials (1)
NCT04711148A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 2Phase 2
Clinical Trials (1)
NCT07082686A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Phase 2Tafasitamab and Lenalidomide
DLBCLClinical Trials (1)
NCT05552937Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Phase 2ICP-332 Tablets
Plaque PsoriasisClinical Trials (1)
NCT07251998Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Phase 2ICP-322
Prurigo Nodularis (PN)Clinical Trials (1)
NCT07236099Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Phase 2Phase 2
Clinical Trials (1)
NCT05678270A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2Orelabrutinib High dose
Mantle Cell LymphomaClinical Trials (1)
NCT05978739Evaluating Different Doses of Orelabrutinib in MCL
Phase 2Phase 2
Clinical Trials (1)
NCT04438005A Study of ICP-022 in Patients With R/R DLBCL
Phase 2Orelabrutinib
Primary Immune ThrombocytopeniaClinical Trials (1)
NCT05232149A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
Phase 2Phase 2
Clinical Trials (1)
NCT05702268Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
Phase 2ICP-022
MZLClinical Trials (1)
NCT03797456A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
Phase 2ICP-192
Bladder Urothelial CancerClinical Trials (1)
NCT04492293An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
Phase 2ICP-022
PCNSLClinical Trials (1)
NCT04438044A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
Phase 2Orelabrutinib
Systemic Lupus Erythematosus, SLEClinical Trials (1)
NCT05688696Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Phase 2ICP-488 Tablets
Cutaneous Lupus Erythematosus (CLE)Clinical Trials (1)
NCT07440537Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
Phase 2ICP-248
Hematologic MalignanciesClinical Trials (1)
NCT06378138ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Phase 2/3ICP-332 Tablets
Chronic Spontaneous Urticaria (CSU)Clinical Trials (1)
NCT07378527Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Phase 2/3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2024
Portfolio: 60 clinical trials